Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

NCT02203773 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02203773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02203773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
October 6, 2014
Completion date
June 16, 2022
Enrollment
212 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelogenous leukemia, treatment naive aml